Search clinical trials for: PI3Kbeta Inhibitor AZD8186

Total 64034 results

National Cancer Institute (NCI)

Active, not recruiting

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

Sensitivity in Esophagus

Denmark, Sweden
Dizal Pharmaceuticals

Not yet recruiting

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Australia
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
AstraZeneca

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Spain, Canada, United Kingdom, Italy, Germany, Australia, United States, Taiwan, France, Korea, Republic of, China
Dizal Pharmaceuticals

Recruiting

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

China
AstraZeneca
Parexel

Terminated

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Type 2 Diabetes

United States
AstraZeneca

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (OA19)

Pain

Bulgaria, Poland, Hungary, Finland, Canada, Slovakia, Japan
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
AstraZeneca

Completed

AZD8566 Food Effect/Microtracer Study

Healthy Volunteer Study

United Kingdom
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Lymphoma, Non-Hodgkin

United States
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca

Completed

AZD1386 Japanese Multiple Ascending Dosing Study (JMAD)

Chronic Pain

Japan
AstraZeneca

Terminated

AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients

COPD

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386 (MAD)

Chronic Pain

United Kingdom
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Terminated

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Healthy

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Insmed Incorporated

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid (PET)

Alzheimer's Disease

Sweden
AstraZeneca

Completed

Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

Pain

United Kingdom
AstraZeneca

Withdrawn

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

Healthy
AstraZeneca

Completed

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Pharmacokinetics
AstraZeneca

Terminated

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

Pain | Neuropathic Pain

France, United Kingdom, Canada, Denmark
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Australia, Taiwan
AstraZeneca

Completed

AZD8108 SAD/MAD in Healthy Volunteers (AZD8108)

Healthy Volunteers

United States
AstraZeneca

Completed

AZD8683 Single Ascending Dose Study

Healthy Volunteers

United States
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Healthy Volunteer

United Kingdom
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Healthy Volunteers

Pain | Esophageal Sensitivity

Sweden, Denmark
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

Pharmacokinetics

United Kingdom
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
AstraZeneca

Completed

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

Capsaicin Evoked Pain | Heat Sensitivity
Seoul National University Bundang Hospital

Unknown

AZD8186 and Paclitaxel in Advanced Gastric Cancer

Stomach Cancer | Solid Tumor

Korea, Republic of
AstraZeneca

Terminated

Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid (PET)

Alzheimer´s Disease

Sweden
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen

Asthma

Canada
AstraZeneca

Completed

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (AZD2816)

COVID-19 | SARS-CoV-2

United Kingdom, Brazil, South Africa, Poland
AstraZeneca

Completed

Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study

Safety, Pharmacokinetics, Pharmacodynamics, Food Effect

United Kingdom
Federal University of Minas Gerais

Unknown

Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery

Obesity | Bariatric Surgery Candidate

Brazil
AstraZeneca

Completed

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386

Pain

United States
AstraZeneca
Syneos Health

Completed

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)

Advanced Solid Tumours

United States, Spain, Korea, Republic of, United Kingdom
AstraZeneca

Completed

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Healthy Subjects

United Kingdom
AstraZeneca

Terminated

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease | COPD

Poland, Sweden
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
Samsung Medical Center

Recruiting

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention (PRESTIGE-AMI)

Heart Failure | Acute Myocardial Infarction

Korea, Republic of
Pfizer

Completed

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)

Metastatic Breast Cancer

Spain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China

3

Subscribe